Hypertrophic Cardiomyopathy Clinical Trial
Official title:
Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve
The aim of this study is to assess microvascular function as determined by a cardiovascular magnetic resonance measurement of whole-heart (global) perfusion reserve. The goal is to determine the prevalence of MVD in two common forms of non-ischemic cardiomyopathy, hypertrophic cardiomyopathy (HCM) and idiopathic dilated cardiomyopathy (IDCM). The hypothesis that an optimized technique will provide robust detection of MVD and that a multifaceted approach will provide new insights into the pathophysiology of MVD, including the influence of myocardial scarring upon the presence and severity of MVD.
Coronary microvascular dysfunction (MVD) has been implicated as an important marker of
cardiac risk and has been thought to directly contribute to the pathogenesis of a wide
variety of cardiomyopathies. For instance, MVD is believed to cause ischemia (with reduction
in coronary flow reserve) in patients with hypertrophic cardiomyopathy (HCM) despite the
presence of angiographically normal epicardial coronary arteries. The implication is that MVD
in HCM may lead to the ventricular arrhythmias, sudden death, and heart failure. Similarly,
patients with idiopathic dilated cardiomyopathy (IDCM) have blunted coronary flow reserve,
which appears to be independently associated with poor prognosis.
Several etiologic mechanisms have been proposed to explain the occurrence of MVD, including
structural and functional abnormalities1:
1. increased microvascular resistance due to reduced vascular luminal caliber.
2. reduced density of microvessels associated with replacement scarring.
3. inappropriate vasoconstrictor responses.
4. inadequate vasodilator responses.
Unfortunately, these mechanisms are difficult to study in humans since no technique currently
allows the direct visualization of the coronary microcirculation in vivo. Thus, MVD has been
largely studied using non-invasive imaging techniques, such as positron emission tomography
(PET) or single photon emitted computed tomography (SPECT).
Although these methods have provided insight into MVD, much remains unknown. For example,
even the prevalence of MVD in patients with various types of cardiomyopathy is unclear, with
different studies showing widely different rates.
Cardiovascular magnetic resonance (CMR) is increasingly being used in clinical practice to
evaluate cardiac disease. CMR employs a multifaceted imaging approach with separate
techniques used to acquire separate sets of raw data, providing information on cardiac
morphology, function, regional myocardial ischemia, scarring, and global myocardial perfusion
reserve. The advantage of this approach is that image artifacts in one set of data will not
affect the quality of the other datasets, and the datasets in combination can be used to
distinguish separate pathophysiologies that could confound image interpretation. For example,
perfusion defects could be due to ischemia or scar tissue, but since the investigators will
obtain both perfusion images and scar images, the investigators will be able to resolve the
etiology. Additionally, CMR provides high spatial resolution (over 10-fold higher than PET),
and hence partial volume affects will be kept to a minimum and variability in measurements
will be reduced.
The aim of this study is to assess microvascular function as determined by a cardiovascular
magnetic resonance measurement of whole-heart (global) perfusion reserve. The goal is to
determine the prevalence of MVD in two common forms of non-ischemic cardiomyopathy,
hypertrophic cardiomyopathy (HCM) and idiopathic dilated cardiomyopathy (IDCM). The
hypothesis that an optimized technique will provide robust detection of MVD and that a
multifaceted approach will provide new insights into the pathophysiology of MVD, including
the influence of myocardial scarring upon the presence and severity of MVD.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03846297 -
Optimisation of Decision Making for Defibrillator Implantation in Hypertrophic Cardiomyopathy
|
||
Completed |
NCT02806479 -
Hypertrophic Cardiomyopathy Pilot Study
|
||
Active, not recruiting |
NCT01225978 -
Refining Information Technology Support for Genetics in Medicine
|
N/A | |
Completed |
NCT00001632 -
Investigation Into the Use of Ultrasound Technique in the Evaluation of Heart Disease
|
N/A | |
Completed |
NCT00001534 -
Long Term Effects of Enalapril and Losartan on Genetic Heart Disease
|
N/A | |
Enrolling by invitation |
NCT04050579 -
OPIE in the Thin Interventricular Septum
|
N/A | |
Completed |
NCT03537183 -
Will Elevated Left Ventricle Filling Pressures Decrease by a Group Exercise Program in Patients With Hypertrophic CardioMyopathy?
|
N/A | |
Completed |
NCT02590809 -
Hypertrophic Cardiomyopathy Symptom Release by BX1514M
|
Phase 2 | |
Completed |
NCT00001396 -
Natural History and Results of Dual Chamber (DDD) Pacemaker Therapy of Children With Obstructive Hypertrophic Cardiomyop...
|
Phase 1 | |
Active, not recruiting |
NCT03723655 -
A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
|
Phase 2/Phase 3 | |
Completed |
NCT05135871 -
Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects
|
Phase 1 | |
Completed |
NCT04129905 -
Assessment of the Relations Between Endothelial and Venous Dysfunctions and Left Ventricular Obstruction in Genetic Hypertrophic Cardiomyopathies
|
N/A | |
Recruiting |
NCT03061994 -
Metabolomic Study of All-age Cardiomyopathy
|
N/A | |
Completed |
NCT02234336 -
Assessment of Wall Thickness in Hypertrophic Cardiomyopathy
|
||
Recruiting |
NCT00221832 -
Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases
|
N/A | |
Not yet recruiting |
NCT03706001 -
Efficacy of Psychotherapy for Improving Quality of Life in Patients With Hypertrophic Cardiomyopathy and Depression
|
N/A | |
Recruiting |
NCT06169358 -
Screening Patients With Fabry Disease in Patients With Hypertrophic Cardiomyopathy or Left Ventricular Hypertrophy
|
||
Not yet recruiting |
NCT04090437 -
HCM-AF Ablation With ACUTUS
|
N/A | |
Completed |
NCT04402268 -
Efficacy of Risk Assessment for Sudden Cardiac Death in Patients With Hypertrophic Cardiomyopathy
|
||
Recruiting |
NCT04112290 -
A Prospective Incident Study of Arrhythmias in Hypertrophic Cardiomyopathy
|